Chr. Hansen Holding A/S (CHYHY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Chr. Hansen Holding A/S (CHYHY) with AI Score 48/100 (Weak). Chr. Hansen Holding A/S develops natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural industries. Market cap: 0, Sector: Basic materials.
Last analyzed: Mar 16, 2026Chr. Hansen Holding A/S (CHYHY) Materials & Commodity Exposure
Chr. Hansen Holding A/S, a bioscience company founded in 1843, develops and sells natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural sectors. Operating globally, the company focuses on cultures, enzymes, and probiotics that enhance food quality and health, with a growing emphasis on sustainable agriculture through strategic collaborations.
Investment Thesis
Chr. Hansen Holding A/S presents a compelling investment case due to its established position in the bioscience industry and its focus on natural ingredient solutions. The company's diverse product portfolio, catering to both food and health sectors, provides resilience against market fluctuations. A key value driver is the increasing demand for natural and sustainable products, aligning with Chr. Hansen's expertise in microbial-based solutions. The strategic collaboration with UPL Ltd. to develop bio solutions for agriculture represents a significant growth catalyst. However, investors may want to evaluate the risks associated with operating in a highly regulated industry and potential fluctuations in raw material prices. The company's beta of 0.31 indicates relatively low volatility compared to the broader market.
Based on FMP financials and quantitative analysis
Key Highlights
- Chr. Hansen operates in the bioscience industry, focusing on natural ingredient solutions for food, nutritional, pharmaceutical, and agricultural sectors.
- The company's Food Cultures & Enzymes segment enhances taste, flavor, texture, shelf life, and nutritional value of food products, primarily in the dairy industry.
- The Health & Nutrition segment provides solutions for dietary supplements, over-the-counter pharmaceuticals, infant formula, animal feed, and plant protection.
- Chr. Hansen has a strategic collaboration with UPL Ltd. to develop and commercialize microbial-based bio solutions for sustainable agriculture.
- The company was founded in 1843 and is headquartered in Hørsholm, Denmark, with a global presence across Europe, the Middle East, Africa, North America, Latin America, and the Asia Pacific.
Competitors & Peers
Strengths
- Strong brand reputation and market position.
- Diverse product portfolio across multiple industries.
- Global presence and distribution network.
- Focus on innovation and research and development.
Weaknesses
- Dependence on specific industries, such as dairy.
- Exposure to fluctuations in raw material prices.
- Potential impact from regulatory changes.
- OTC market trading may limit liquidity.
Catalysts
- Ongoing: Increasing demand for natural and sustainable solutions in the food and agriculture industries.
- Ongoing: Expansion in emerging markets, particularly in the Asia Pacific region.
- Upcoming: Potential for new product launches and innovations in food cultures and enzymes.
- Ongoing: Strategic collaborations and partnerships to expand product portfolio and geographic reach.
- Ongoing: Growing consumer awareness of the health benefits of probiotics.
Risks
- Potential: Intense competition from other bioscience companies.
- Potential: Economic downturns affecting consumer spending.
- Potential: Changes in consumer preferences and trends.
- Potential: Product recalls or safety concerns.
- Ongoing: Fluctuations in raw material prices.
Growth Opportunities
- Expansion in Sustainable Agriculture: Chr. Hansen's collaboration with UPL Ltd. to develop microbial-based bio solutions for agriculture presents a significant growth opportunity. The market for sustainable agriculture is expanding rapidly, driven by increasing environmental concerns and regulatory pressures. This partnership allows Chr. Hansen to leverage its expertise in microbial solutions to address the growing demand for environmentally friendly agricultural practices. This market is projected to reach multi-billion dollars in the next five years, offering substantial revenue potential.
- Increased Demand for Probiotic Solutions: The growing consumer awareness of the health benefits of probiotics is driving demand for Chr. Hansen's Health & Nutrition segment. The global probiotics market is expected to continue its strong growth trajectory, fueled by increasing research and development in probiotic applications. Chr. Hansen's established position in this market, coupled with its focus on innovation, positions the company to capitalize on this trend. The probiotics market is projected to reach over $90 billion by 2030.
- Geographic Expansion in Emerging Markets: Chr. Hansen has the opportunity to expand its presence in emerging markets, particularly in the Asia Pacific region. These markets are experiencing rapid economic growth and increasing demand for processed foods and health products. By leveraging its existing product portfolio and establishing strategic partnerships, Chr. Hansen can tap into these high-growth markets. The Asia Pacific region is expected to be the fastest-growing market for food enzymes and cultures.
- Innovation in Food Cultures and Enzymes: Chr. Hansen can drive growth through continued innovation in its Food Cultures & Enzymes segment. Developing new and improved cultures and enzymes that enhance the taste, texture, and shelf life of food products can create a competitive advantage. The company's focus on research and development allows it to stay ahead of market trends and meet the evolving needs of its customers. The market for innovative food cultures and enzymes is constantly evolving, driven by consumer demand for healthier and more convenient food options.
- Strategic Acquisitions and Partnerships: Chr. Hansen can pursue strategic acquisitions and partnerships to expand its product portfolio and geographic reach. Acquiring companies with complementary technologies or market positions can accelerate growth and create synergies. The company's strong financial position allows it to pursue these opportunities and enhance its competitive advantage. Strategic partnerships can also provide access to new markets and technologies, further driving growth.
Opportunities
- Expansion in emerging markets.
- Growing demand for natural and sustainable solutions.
- Strategic acquisitions and partnerships.
- Development of new and innovative products.
Threats
- Intense competition from other bioscience companies.
- Economic downturns affecting consumer spending.
- Changes in consumer preferences and trends.
- Potential for product recalls or safety concerns.
Competitive Advantages
- Proprietary microbial technology and intellectual property.
- Established relationships with key customers in the food and health industries.
- Global presence and distribution network.
- Strong focus on research and development and innovation.
About CHYHY
Founded in 1843 and headquartered in Hørsholm, Denmark, Chr. Hansen Holding A/S has evolved into a global bioscience leader. The company specializes in developing natural ingredient solutions for a diverse range of industries, including food, nutrition, pharmaceuticals, and agriculture. Chr. Hansen operates through two primary segments: Food Cultures & Enzymes and Health & Nutrition. The Food Cultures & Enzymes segment focuses on producing cultures, enzymes, and probiotic products that enhance the taste, flavor, texture, shelf life, nutritional value, and health benefits of food products, particularly in the dairy industry. The Health & Nutrition segment provides solutions for dietary supplements, over-the-counter pharmaceuticals, infant formula, animal feed, and plant protection. Chr. Hansen's geographic reach spans Europe, the Middle East, Africa, North America, Latin America, and the Asia Pacific region. The company also engages in strategic collaborations, such as its partnership with UPL Ltd., to develop and commercialize microbial-based bio solutions for sustainable agriculture, reflecting its commitment to innovation and environmental responsibility.
What They Do
- Develops natural ingredient solutions for the food industry.
- Produces cultures and enzymes for dairy products.
- Offers probiotic products for health and nutrition.
- Provides solutions for the pharmaceutical industry.
- Creates products for the agricultural industry.
- Collaborates to develop microbial-based bio solutions.
- Enhances the taste, texture, and shelf life of food products.
Business Model
- Develops and manufactures cultures, enzymes, and probiotics.
- Sells products to food, nutritional, pharmaceutical, and agricultural companies.
- Generates revenue through product sales and licensing agreements.
- Focuses on innovation and research and development to create new products.
Industry Context
Chr. Hansen operates within the specialty chemicals industry, which is experiencing growth driven by increasing demand for sustainable and natural solutions. The market is characterized by intense competition and evolving consumer preferences. The global market for food enzymes and cultures is projected to reach billions of dollars, driven by the rising demand for processed and functional foods. Chr. Hansen is well-positioned to capitalize on these trends through its focus on innovation and strategic partnerships. The company's emphasis on microbial-based solutions aligns with the growing demand for sustainable agricultural practices.
Key Customers
- Food manufacturers, particularly in the dairy industry.
- Dietary supplement companies.
- Pharmaceutical companies.
- Agricultural businesses.
Financials
Chart & Info
Chr. Hansen Holding A/S (CHYHY) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Lows On Monday
· Jan 27, 2020
-
Stocks That Hit 52-Week Lows On Thursday
· Oct 10, 2019
-
Stocks That Hit 52-Week Lows Of Monday
· Aug 12, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CHYHY.
Price Targets
Wall Street price target analysis for CHYHY.
MoonshotScore
What does this score mean?
The MoonshotScore rates CHYHY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Mauricio Graber
CEO
Mauricio Graber serves as the CEO of Chr. Hansen Holding A/S. His career spans various leadership roles in the food and beverage industry. He has a strong background in strategic management and global operations. Prior to joining Chr. Hansen, he held key positions at major multinational corporations, demonstrating expertise in driving growth and innovation. His experience includes overseeing large teams and managing complex business operations across diverse geographic regions.
Track Record: Under Mauricio Graber's leadership, Chr. Hansen has focused on expanding its presence in emerging markets and strengthening its position in sustainable agriculture. He has overseen strategic collaborations to develop innovative solutions and has driven initiatives to enhance the company's operational efficiency. His tenure has been marked by a commitment to innovation and a focus on meeting the evolving needs of customers.
CHYHY OTC Market Information
The OTC Other tier represents the lowest tier of over-the-counter (OTC) markets. Companies in this tier often have limited or no financial disclosure requirements and may not meet minimum listing standards. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, resulting in higher information asymmetry and potential risks for investors. These companies may not be required to file regular reports with the SEC, making it difficult for investors to assess their financial health and operational performance. This tier is often associated with speculative investments and should be approached with caution.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure requirements.
- Lower trading volume and liquidity.
- Potential for wider bid-ask spreads.
- Higher information asymmetry.
- Increased risk of fraud or manipulation.
- Verify the company's registration and legal status.
- Assess the company's financial health and operational performance.
- Research the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal issues.
- Established history in the bioscience industry.
- Global presence and distribution network.
- Strategic collaborations with reputable companies.
- Focus on innovation and research and development.
- Operations managed by Mauricio Graber.
Chr. Hansen Holding A/S Stock: Key Questions Answered
What does Chr. Hansen Holding A/S do?
Chr. Hansen Holding A/S is a bioscience company that develops and produces natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural industries. The company operates through two segments: Food Cultures & Enzymes, which provides cultures, enzymes, and probiotics to enhance food quality, and Health & Nutrition, which offers solutions for dietary supplements, pharmaceuticals, and animal feed. Chr. Hansen's products improve taste, texture, shelf life, and health benefits, contributing to a more sustainable and healthier world.
What do analysts say about CHYHY stock?
AI analysis is pending for CHYHY stock. Generally, analysts consider factors such as the company's financial performance, growth prospects, and competitive positioning within the bioscience industry. Key valuation metrics include price-to-earnings ratio, price-to-sales ratio, and enterprise value-to-EBITDA. Growth considerations include the company's ability to expand into new markets, develop innovative products, and maintain its market share. The beta of 0.31 suggests lower volatility than the market average.
What are the main risks for CHYHY?
The main risks for Chr. Hansen Holding A/S include intense competition from other bioscience companies, potential economic downturns affecting consumer spending, and changes in consumer preferences and trends. Fluctuations in raw material prices and the potential for product recalls or safety concerns also pose risks. As an OTC-traded stock, CHYHY faces additional risks related to limited liquidity, lower financial disclosure requirements, and increased information asymmetry, which can impact investment decisions.
What are the key factors to evaluate for CHYHY?
Chr. Hansen Holding A/S (CHYHY) currently holds an AI score of 48/100, indicating low score. Key strength: Strong brand reputation and market position.. Primary risk to monitor: Potential: Intense competition from other bioscience companies.. This is not financial advice.
How frequently does CHYHY data refresh on this page?
CHYHY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CHYHY's recent stock price performance?
Recent price movement in Chr. Hansen Holding A/S (CHYHY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong brand reputation and market position.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CHYHY overvalued or undervalued right now?
Determining whether Chr. Hansen Holding A/S (CHYHY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CHYHY?
Before investing in Chr. Hansen Holding A/S (CHYHY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data may be limited due to OTC status.
- AI analysis is pending.